BiotechTube
CASI Pharmaceuticals

CASI Pharmaceuticals

CASI
United States
casipharmaceuticals.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

CASI · Stock Price

USD 0.14-0.01 (-5.65%)
Market Cap: $2.2M

Historical price data

Overview

CASI Pharmaceuticals' mission is to address urgent unmet medical needs in organ transplant rejection and autoimmune diseases through its lead candidate, CID-103. The company has established a commercial footprint in China with products like EVOMELA® and FOLOTYN®, generating revenue to support its R&D. Its strategy hinges on advancing CID-103 as a first-in-class therapy for AMR while leveraging its China commercial platform for sustainable growth. Key achievements include building a dual-region management team and advancing CID-103's preclinical and clinical development.

Organ Transplant RejectionAutoimmune DiseasesOncology

Technology Platform

Monoclonal antibody platform targeting the CD38 glycoprotein on plasma and NK cells, with a focus on epitope-specific binding (R78) to optimize effector functions and reduce off-target binding.

Pipeline

24
24 drugs in pipeline
DrugIndicationStageWatch
Melphalan Hydrochloride for InjectionMultiple MyelomaApproved
Panzem NCD + TemozolomideRecurrent Glioblastoma MultiformePhase 2
MKC-1Ovarian CancerPhase 2
Panzem (2-methoxyestradiol) NCD, Avastin (Bevacizumab)Carcinoid TumorPhase 2
ENMD-2076Ovarian CancerPhase 2

Funding History

4
Total raised:$70M
PIPE$25M
IPO$15M
Series B$20M
Series A$10M

Opportunities

CID-103 addresses a massive unmet need with no FDA-approved therapies for Antibody-Mediated Rejection (AMR), representing a first-in-class opportunity.
A successful subcutaneous formulation could capture significant market share in transplant and chronic autoimmune settings due to superior patient convenience.
The China commercial business provides a foundational revenue stream to fund development.

Risk Factors

Extreme clinical risk as CID-103 is in early-stage trials with unproven efficacy in AMR/autoimmunity.
The company faces severe financial and liquidity constraints, with a micro-cap valuation making non-dilutive funding challenging.
It competes with large pharma companies repurposing approved anti-CD38 drugs and must successfully execute a complex dual-region operational strategy.

Competitive Landscape

CID-103 competes directly with Janssen's daratumumab and Sanofi's isatuximab, which are being investigated in similar indications and have vast resources. It also competes with the current standard of care for AMR (rituximab, IVIG, plasmapheresis) and a pipeline of other novel agents. Differentiation is claimed through epitope-specific binding and optimized effector function.

More companies in Biologics / Biosimilars →More companies in United States →